Drug Trial Radar · NCT04745832
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
Last checked: Nov 19, 2026Latest source record: Nov 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
82
Actual
Start
Aug 13, 2021
Primary completion
Mar 20, 2023
Study completion Mar 20, 2023
Sponsor
- Lead sponsor
- MEI Pharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Kyowa Kirin, Inc.
- First posted
- Feb 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3 study of the PI3Kδ inhibitor Zandelisib (ME-401) in combination with rituximab, in comparison to standard immunochemotherapy (Rituximab-Bendamustine or Rituximab-CHOP) in subjects with relapsed or refractory FL and MZL.
Conditions
- Follicular Lymphoma (FL)
- Non Hodgkin Lymphoma
- Marginal Zone Lymphoma
Interventions
ZandelisibDrug
Zandelisib 60 mg capsules taken daily for two cycles followed by intermittent schedule starting at Cycle 3
RituximabDrug
Rituximab IV 375 mg/m2 for 6 cycles
BendamustineDrug
Bendamustine IV 90 mg/m2 on Days 1 and 2 for 6 cycles
CHOPDrug
Cyclophosphamide, Vindcristine IV, and Prednisone daily orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free SurvivalTime frame: 1 year 7 months
Locations
141 sites in 19 countries. Site status is shown where the registry gives one.
The Oncology Institute of Hope and Innovation
Tucson, Arizona
Orange Coast Memorial Medical Center
Fountain Valley, California
Long Beach Memorial Medical Center
Long Beach, California
The Oncology Institute of Hope and Innovation
Riverside, California
BRCR Medical Center Inc
Hollywood, Florida
Henry Ford Hospital
Detroit, Michigan
Revive Research Institute
Farmington Hills, Michigan
Revive Research Institute
Sterling Heights, Michigan
Mercy Clinic Cancer & Hematology - Chub O'Reilly Cancer Center
Springfield, Missouri
Inspira Medical Center Mullica Hill
Mullica Hill, New Jersey
MetroHealth Medical Center
Cleveland, Ohio
Alpha Research Institute, LLC
Baytown, Texas
Valley Cancer Associates
Harlingen, Texas
Community Cancer Trials of Utah
Ogden, Utah
Canberra Hospital
Garran, Australia
The Perth Blood Institute (PBI)
West Perth, Australia
Westmead Hospital
Westmead, Australia
AZ Sint-Jan Burgge-Oostende AV
Bruges, Belgium
UZ Brussel
Brussels, Belgium
Universitair Ziekenhuis Antwerpen
Edegem, Belgium
Center Hospitalier de Jolimont
Haine-Saint-Paul, Belgium
UZ Leuven Campus Gasthuisberg
Leuven, Belgium
McGill University Health Centre
Québec, Canada
Eastern Regional Health Authority
St. John's, Newfoundland and Labrador, Canada
Centre intégré universitaire de santé et de services sociaux de l'Estrie
Sherbrooke, Quebec, Canada
CHU Estaing. Service d'hématologie clinique et de thérapie cellulaire adulte,
Clermont-Ferrand, France
Centre Hospitalier De Dunkerque - Service d'hématologie
Le Mans, France
Centre Hospitalier du Mans
Le Mans, France
Centre Leon Berard
Lyon, France
Hôpital Saint-Louis
Paris, France
CHU de Bordeaux - Maladies Du Sang, Centre François Magendie
Pessac, France
Centre Henri Becquerel, Service d'Hematologie
Rouen, France
CHU de Tours, Hôpital Bretonneau Centre
Tours, France
Institut De Cancerologie Gustave Roussy
Villejuif, France
LTD Israeli-Georgian Medical Research Clinic "Helsicore"
Tbilisi, Georgia
M. Zodelava Hematology Center
Tbilisi, Georgia
J.S.C. K. Eristavi National Center of Experimental and Clinic
Tbilisi, Georgia
LTD "Medinvest" Institute of Hematology and Transfusiology
Tbilisi, Georgia
General Hospital of Athens "Laiko", Department of Haematology and Bone Marrow Transplantation
Athens, Greece
University General Hospital of Ioannina, Department of Haematology
Ioannina, Greece
Showing 40 of 141 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.